The microbiota of patients with psoriasis are less diverse compared with healthy controls. Moreover, psoriasis patients show a decreased functional richness compared with both healthy controls and healthy partners that live in the same household.
Advances in technology have led to an increased number of studies investigating the microbiome in patients with inflammatory diseases. Growing evidence supports an altered gut microbiota in patients with psoriasis. Culture-based studies have identified an increased presence of oral Candida in patients with psoriasis [1]. Interestingly, probiotics have been associated with a significant improvement in the severity of psoriasis but did not change microbiota [1]. “There is an association, but, according to our recently published review, the results are quite heterogeneous,” Dr Tanja Todberg (University of Copenhagen, Denmark) explained [1,2]. This can in part be explained by poor study design with most studies lacking relevant inclusion criteria and baseline information [1].To further assess microbiota in psoriasis, Dr Todberg and colleagues defined 3 different research questions: Do patients with psoriasis exhibit an aberrant gut microbial profile compared with healthy individuals? Do patients with psoriasis exhibit an aberrant gut microbial profile compared with their healthy partners that live in the same house? And is the known seasonal change of psoriasis severity associated with a shift in the composition of the gut microbiota?
The researchers collected 126 faecal samples: 53 from patients with plaque psoriasis without systemic treatment, another 52 from healthy controls matched for age, sex, body mass index (BMI), and geographical location, and 21 of the healthy cohabitants of the psoriasis patients. All participants with psoriasis had to have a Psoriasis Area Severity Index (PASI) score of ≥8, restriction of antibiotics and systemic anti-inflammatory treatment for >3 months, and a BMI <35. Patients with diabetes or other inflammatory conditions were excluded. “We assessed patients with more severe disease to be able to see a difference. There is definitely a correlation between differences in gut microbiota and increasing severity of disease,” Dr Todberg explained.
“Our psoriasis patients had moderate-to-severe disease with early-onset and a normal weight. What separated them from the control group is that they smoked significantly more, and their level of physical activity was significantly lower,” Dr Todberg said. The microbial composition of the patients with psoriasis was characterised by a significantly lower richness (P=0.007) and difference in community composition (P=0.01) of metagenomic species compared with healthy controls. Moreover, the functional richness was decreased in patients with psoriasis compared with healthy controls (P=0.01) and partners (P=0.05). Interestingly, no seasonal differences were detectable in the gut microbiota.
In conclusion, the study showed that patients with psoriasis exhibit a dysbiotic taxonomic and functional gut microbiota compared with age, sex, and BMI-matched healthy controls. Despite the similar environment, a significantly lower microbial diversity was seen in patients with psoriasis compared with their partners (P=0.04). As Dr Todberg commented in the discussion, a pilot study examined the effect of adalimumab on gut microbiota in 10 psoriasis patients. Although the therapy had a very positive impact on the skin lesions, the gut microbiota stayed the same, even after 5–6 months of adalimumab therapy.
- Â Todberg T, et al. Acta Derm Venereol. 2021;101(7):dv00512.
- Todberg T, et al. Characteristics of the gut microbiota in patients with psoriasis. FC09, Psoriasis from Gene to Clinic 2021, 9–11 December.
Copyright ©2021 Medicom Medical Publishers
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Psoriasis associated with a higher cancer risk Next Article
Intermediate monocytes are possible predictors of response to secukinumab »
« Psoriasis associated with a higher cancer risk Next Article
Intermediate monocytes are possible predictors of response to secukinumab »
Table of Contents: PFGC 2021
Featured articles
Letter from the Editor
Guselkumab shows highest drug survival among systemic treatments
Genes in Psoriasis and Psoriatic Arthritis
HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario
Protective factors identified against anti-drug antibody formation to adalimumab in psoriasis
Comorbidity in Psoriasis
Psoriasis associated with a higher cancer risk
Comorbidity and clinical features of psoriasis vary according to HLA-C*06:02 status
Psoriasis patients with cardiovascular comorbidity characterised by high systemic inflammation
Psoriasis Therapy: New Findings
Inhibition of heat shock protein: A novel way to treat psoriasis?
Guselkumab shows highest drug survival among systemic treatments
Tapering biologics: No alarming signs of increased anti-drug antibodies
Intermediate monocytes are possible predictors of response to secukinumab
Gut microbiota of psoriasis patients: less diverse and reduced functionality
COVID-19: What's New
DLQI scores underestimated during lockdowns?
TNF blockers likely beneficial for psoriatic patients with COVID-19
Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion
Paradoxical Reactions to Biologics
The Yin and Yang of opposing vectors: an explanation for side effects of biologics
Explaining arthropathy development through IL-4 and IL-13 blockade
Best of the Posters
Potential biomarker discovered for treatment response to ustekinumab
TNF inhibitor for immune-mediated inflammatory disease doubles the risk of paradoxical psoriasis
Secukinumab also tolerable in paediatric psoriasis patients
High treatment success with ixekizumab in patients with psoriasis and diabetes
Related Articles
August 6, 2020
Biologic psoriasis treatment to lower cardiovascular risk?
June 21, 2019
Small molecules, apremilast, and TYK2
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy